sglt-2 inhibitors and more practice changing data from esc 2019
Published 4 years ago • 62 plays • Length 22:06Download video MP4
Download video MP3
Similar videos
-
0:40
sglt-2 inhibitors promising for heart failure prevention, not treatment
-
12:49
esc tv conversations - sglt2 inhibitors – wonder drugs in heart failure and beyond?
-
7:03
dapa-hf: dapagliflozin’s hfref efficacy confirmed in nondiabetics
-
0:30
sglt2 inhibitors for diabetics
-
16:10
how sglt-2 inhibitors work: with pros and cons - jardiance, farxiga, invokana -type 2 diabetes#15
-
2:25:41
sglt2 inhibitor (dapagliflozin) trials in diabetes, kidney disease and heart failure.
-
10:55
what are sglt2 inhibitors and how do they affect kidney disease?
-
8:44
long-awaited ischemia results to change practice, dapa-hf elevates dapagliflozin for hfref
-
8:15
sglt2 inhibitors and heart failure
-
20:13
sglt2 inhibitors in heart failure management with dr. john mcmurray
-
2:44
sglt2 inhibitors explained in 3 minutes
-
6:57
how does dapagliflozin work? understanding sglt2 inhibitors.
-
22:15
sglt-2 inhibitors for type 2 diabetes - amel arnaout, md
-
11:01
why sglt2 inhibitors cause euglycemic dka
-
25:32
dr julie lovshin - sglt2i cardiorenal mechanisms in diabetes and beyond - full presentation
-
59:01
initiating and managing sglt2 inhibitors in type 2 diabetes webinar
-
3:23
what are sglt2 inhibitors - chronic kidney disease | uhl nhs trust
-
8:32
dr julie lovshin - sglt2i cardiorenal mechanisms in diabetes and beyond - summary presentation
-
3:45
diabetes type 1 and type 2, animation.
-
2:27
cardiovascular benefit with sglt2 inhibition